Lipid Nanoparticle Formulations for the Skin Delivery of Cannabidiol
2024

Lipid Nanoparticle Formulations for Skin Delivery of Cannabidiol

publication 10 minutes Evidence: moderate

Author Information

Author(s): Calienni Maria Natalia, Scavone Mirian Ana, Sanguinetti Ana Paula, Corleto Merlina, Di Meglio Magalí Rocío, Raies Pablo, Cristos Diego Sebastián, Maffia Paulo César, Montanari Jorge

Primary Institution: Universidad Nacional de Hurlingham (UNAHUR)

Hypothesis

Can lipid nanoparticles effectively deliver cannabidiol to deeper layers of the skin while maintaining its stability and antibacterial properties?

Conclusion

The developed cannabidiol nanoformulations show potential for treating skin diseases by enhancing delivery and exhibiting antibacterial effects.

Supporting Evidence

  • Three nanoformulations exhibited the best size and reproducibility values.
  • The formulations were stable and protected the active ingredient.
  • They succeeded in delivering cannabidiol to deep skin layers.
  • The formulations demonstrated antibacterial activity against Staphylococcus aureus.
  • Encapsulation increased the stability of cannabidiol over time.
  • Skin penetration assays showed improved delivery of cannabidiol compared to free cannabidiol.
  • All three CBD-loaded nanoparticles exhibited the same minimal inhibitory concentration against bacteria.

Takeaway

This study created tiny particles to help deliver a natural compound called cannabidiol into the skin better, which could help with skin problems.

Methodology

Solid lipid nanoparticles and nanostructured lipid carriers were prepared and characterized for their properties, stability, and skin penetration using human skin samples.

Limitations

The study primarily used in vitro models and human skin samples from a single donor, which may limit the generalizability of the findings.

Participant Demographics

Human skin samples were obtained from a healthy 45-year-old Caucasian woman.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/pharmaceutics16121490

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication